YD Bio director exercises RSUs, updates holdings
YD Bio Ltd director Lu Shao-Ta reported equity compensation activity and updated share holdings.
Rhea-AI Filing Summary
YD Bio Ltd director Lu Shao-Ta reported equity compensation activity and updated share holdings. On June 30, 2026, he exercised 5,749 restricted share units (RSUs) into 5,749 ordinary shares at a stated price of $0.00 per share and received a new grant of 5,749 RSUs.
The RSUs relate to a March 31, 2026 award under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments based on a seven‑day volume‑weighted average price. Following these transactions, Lu holds 7,830 ordinary shares directly and 51,151 ordinary shares indirectly through his spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary
5,749 shares exercised/converted
Exercise
4 txns
Insider
Lu Shao-Ta
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Share Units | 5,749 | $0.00 | $0.00 |
| Exercise | Restricted Share Units | 5,749 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 5,749 | $0.00 | $0.00 |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Restricted Share Units — 0 contracts (Direct);
Ordinary Shares — 7,830 shares (Direct);
Ordinary Shares — 51,151 shares (Indirect, By Spouse)
Footnotes (3)
- F1. Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.
- F2. The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.
- F3. The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").
Key Figures
RSUs exercised: 5,749 units
Ordinary shares acquired: 5,749 shares
New RSU grant: 5,749 units
+4 more
7 metrics
RSUs exercised
5,749 units
RSUs converted into ordinary shares on June 30, 2026
Ordinary shares acquired
5,749 shares
Received upon RSU exercise at $0.00 per share
New RSU grant
5,749 units
Grant under Equity Incentive Plan on March 31, 2026
Grant date fair value
$60,000
Aggregate target value of RSU award on March 31, 2026
Quarterly vesting tranche
$15,000
Value per quarterly RSU installment using VWAP formula
Direct ordinary shares
7,830 shares
Direct holdings after June 30, 2026 transactions
Indirect ordinary shares
51,151 shares
Held indirectly through spouse as of June 30, 2026
Key Terms
Restricted Share Units, Equity Incentive Plan, grant date fair value, volume-weighted average price
4 terms
Equity Incentive Plan financial
"The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
grant date fair value financial
"with an aggregate target grant date fair value of $60,000 on March 31, 2026"
The grant date fair value is the estimated dollar worth of a stock-based award (such as stock options or restricted shares) at the exact moment it is given to an employee or contractor. Investors care because companies use that value to record compensation expenses and to show how much potential ownership and earnings dilution those awards could create—think of it as the price tag placed on a gift card when it is handed over so the company can report the cost now.
volume-weighted average price financial
"by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did YD Bio (YDES) director Lu Shao-Ta report?
Lu Shao-Ta reported exercising 5,749 restricted share units (RSUs) into 5,749 ordinary shares at $0.00 per share and receiving a new grant of 5,749 RSUs. These are equity compensation-related, not open-market purchases or sales.
What are the terms of the YD Bio (YDES) RSU grant reported in this filing?
The RSUs were granted under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026. They vest in four equal quarterly installments of $15,000 each, determined using a seven‑day volume‑weighted average price.
How is the number of YD Bio (YDES) RSUs determined at each vesting date?
For each quarterly vesting, the number of RSUs is calculated by dividing $15,000 by the seven trading‑day volume‑weighted average price of YD Bio’s ordinary shares ending the day before the vesting date, according to the equity incentive plan terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
